A Study Assessing KB407 for the Treatment of Cystic Fibrosis
NCT05504837
Recruiting
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: University of Florida, Gainesville, Gainesville, Florida +4 locations
Conditions: Cystic Fibrosis
Register for Updates
Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)
NCT05172271
Recruiting
Background: People with TRD are often helped by electroconvulsive therapy (ECT). But ECT can affect memory and thinking. Researchers want to study a treatment called TEST that uses less electricity. Objective: To study the safety and feasibility of TEST and assess its antidepressant effects. Eligibility: Adults aged 25-64 with major depression that has not been relieved by current treatments. Design: Participants will be admitted to the NIH Clinical Center for 5 18 weeks over 2 3 treatmen... Read More
Gender:
ALL
Ages:
Between 25 years and 64 years
Trial Updated:
08/19/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Register for Updates
Neurobiology of Suicide
NCT02543983
Recruiting
Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies. They hope to better understand suicide, so they can help suicidal people. Objective: To understand what happens in the brain when someone has thought about or attempted suicide. Eligibility: Group 1: Adults ages 18 70 who have thought about or attempted suicide recently Group 2: Adults ages 18 70 who have thought about or... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/19/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteers, Depression
Register for Updates
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06975878
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 15vPCV (Vaxneuvance, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 112 days). The study duration per participant will be up... Read More
Gender:
ALL
Ages:
Between 42 days and 112 days
Trial Updated:
08/19/2025
Locations: Investigational Site Number : 2460001, Houston, Texas +31 locations
Conditions: Pneumococcal Immunization, Healthy Volunteers
Register for Updates
Social & QoL Behaviors in Parkinson's Disease
NCT06385184
Recruiting
Adults with Parkinson's Disease experience an array of challenges and changes in daily living, behaviors, and functioning throughout the progression of their condition. The investigators want to learn more about the effects of Parkinson's Disease on individuals' social behavior and quality of life (QoL) compared to people of the same age without Parkinson's Disease.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/19/2025
Locations: The George Washington University, Washington, District of Columbia
Conditions: Parkinson Disease
Register for Updates
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT04684368
Recruiting
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients... Read More
Gender:
ALL
Ages:
Between 3 years and 29 years
Trial Updated:
08/19/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +162 locations
Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Choriocarcinoma, Suprasellar Germ Cell Tumor
Register for Updates
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease
NCT02504879
Recruiting
Background: - The rare disease melorheostosis causes bones to thicken. This may lead to pain, and can affect bones, joints, and muscles. Researchers want to learn more about the disease and how it progresses. Objective: -To see what happens to people with melorheostosis over time and understand the causes of the disease. Eligibility: * People 18 and over with melorheostosis. * Their unaffected relatives. Design: * All participants will have a medical history and physical exam. * Participa... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/19/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Rheumatic Disease
Register for Updates
A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
NCT06741657
Recruiting
In this study, researchers will learn how the body processes litifilimab when it is given under the skin in 3 different ways. Currently, ongoing studies utilize pre-filled syringes (PFS) that can deliver litifilimab subcutaneously (SC), also known as under the skin. In this study, researchers want to learn more about new ways of delivering litifilimab SC using either an autoinjector (AI) or an on-body injector (OBI): Both devices are designed to deliver litifilimab in an automatic way, especia... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/19/2025
Locations: Las Vegas Clinical Research Unit, Las Vegas, Nevada +1 locations
Conditions: Healthy Volunteer
Register for Updates
Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch
NCT06751056
Recruiting
The purpose of this study is to determine if cervical traction is an effective treatment to reduce GABAergic medication use for scalp, arm, and upper back neuropathic itch.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Pruritus
Register for Updates
A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
NCT05655494
Recruiting
The purpose of this study is to pilot test and evaluate an existing tailored ALEX (Agent Leveraging Empathy for eXams) Research Portal to navigate Black and Hispanic adult cancer patients and their family members through referral to cancer clinical trials.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/19/2025
Locations: University of Florida, Gainesville, Florida +2 locations
Conditions: Cancer
Register for Updates
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906
Recruiting
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy, the blood level of a specific protein called PSA rises. PSA is a marker of prostate cancer cells activity. The PSA increase means that the cancer has come back even though conventional imaging such as computed tomography (CT) scans, magnetic resonance imaging (MRI) and bo... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: City of Hope - Phoenix Cancer Center, Goodyear, Arizona +299 locations
Conditions: Biochemically Recurrent Prostate Cancer
Register for Updates
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
NCT04244630
Recruiting
The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidants would be a simple, low risk, low-cost approach to significantly slow or stop the progression of ALS, for which currently no effective treatment exists. It is currently thought that oxidative stress is a major cause of... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
08/19/2025
Locations: VA North Texas Health Care System, Dallas, Texas
Conditions: Amyotrophic Lateral Sclerosis (ALS)
Register for Updates